DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy

DNA polymeraseη protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy

<p>Abstract</p> <p>Background</p> <p>DNA polymerase η (pol η) is capable of bypassing DNA adducts produced by cisplatin or oxaliplatin and is associated with cellular tolerance to platinum. Previous studies showed that defective pol η resulted in enhanced cisplatin or o...

Full description

Bibliographic Details
Main Authors:	Luo Hui-yan, Li Zhuang-hua, Qiu Miao-zhen, Teng Kai-yuan, Zeng Zhao-lei, Luo Rong-zhen, Zhang Hui-zhong, Wang Zhi-qiang, Li Yu-hong, Xu Rui-hua
Format:	Article
Language:	English
Published:	BMC 2010-11-01
Series:	Journal of Translational Medicine
Online Access:	http://www.translational-medicine.com/content/8/1/126

Similar Items

Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer
by: Zhi-Qiang Wang, et al.
Published: (2016-01-01)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
by: Fattoruso Silvia, et al.
Published: (2009-03-01)

Utilization and Cost-Effectiveness Analysis of Chemotherapy for Metastatic Gastric Adenocarcinoma
by: Wei-Shan Chang, et al.
Published: (2018)

Detection of carcinoembryonic antigen messenger RNA in blood using quantitative real-time reverse transcriptase-polymerase chain reaction to predict recurrence of gastric adenocarcinoma
by: Wang Zhi-qiang, et al.
Published: (2010-10-01)

Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy.
by: Ruixuan Geng, et al.
Published: (2014-01-01)

Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial
by: Haiping Jiang, et al.
Published: (2020-08-01)

Adjuvant chemotherapy for elderly patients with gastric cancer after D2 gastrectomy.
by: Ying Jin, et al.
Published: (2013-01-01)

Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
by: Yan Wang, et al.
Published: (2018-06-01)

A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer
by: Qinchuan Wang, et al.
Published: (2021-01-01)

Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma
by: Gaurav Goel, et al.
Published: (2010-04-01)

Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro
by: Zhao Qun, et al.
Published: (2010-08-01)

P190BCR-ABL Chronic Myeloid Leukemia Following a Course of S-1 Plus Oxaliplatin Therapy For Advanced Gastric Adenocarcinoma
by: Hua Wang, et al.
Published: (2017-01-01)

S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.
by: Ming-ming He, et al.
Published: (2013-01-01)

Efficacy and Safety of Docetaxel Plus Oxaliplatin and Capecitabine in the First Line Treatment of Advanced Gastric Adenocarcinoma
by: Ying Liu, et al.
Published: (2013-01-01)

Oxaliplatin-based chemotherapy is more beneficial in KRAS mutant than in KRAS wild-type metastatic colorectal cancer patients.
by: Yu-Lin Lin, et al.
Published: (2014-01-01)

Sensorimotor Deficits Following Oxaliplatin Chemotherapy
by: Vincent, Jacob Adam
Published: (2017)

Phase II study of adjuvant chemotherapy with S1 plus oxaliplatin for Chinese patients with gastric cancer
by: Guoxiu Wang, et al.
Published: (2018-05-01)

Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin or oxaliplatin for peritoneal metastasis from pancreatic adenocarcinoma and cholangiocarcinoma
by: Andrea Di Giorgio, et al.
Published: (2020-07-01)

Irinotecan combined with oxaliplatin and S-1 in patients with metastatic pancreatic adenocarcinoma: a single-arm, three-centre, prospective study
by: Keke Nie, et al.
Published: (2020-11-01)

Comparison of the Efficacy of S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Six and Eight Chemotherapy Cycles as Adjuvant Chemotherapy in Patients With Stage II-III Gastric Cancer After D2 Resection
by: Yuanyuan Yu, et al.
Published: (2021-05-01)

A New Oxaliplatin Resistance-Related Gene Signature With Strong Predicting Ability in Colon Cancer Identified by Comprehensive Profiling
by: Qiu Lin, et al.
Published: (2021-05-01)

A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy
by: Zhi-jun Yan, et al.
Published: (2018-01-01)

Nomogram for predicting the survival of gastric adenocarcinoma patients who receive surgery and chemotherapy
by: Chao-Yang Wang, et al.
Published: (2020-01-01)

Complete Response of Locally Advanced Gastric Cancer with Pancreatic Invasion and Gastric Outlet Obstruction after Neoadjuvant Chemotherapy with S-1 and Oxaliplatin
by: Masato Kondo, et al.
Published: (2020-06-01)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mohammad Ali Mashhadi, et al.
Published: (2016-10-01)

Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery
by: Liu Y, et al.
Published: (2016-03-01)

Serum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinoma.
by: Shu-Qin Dai, et al.
Published: (2013-01-01)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
by: Huang Che-Jen, et al.
Published: (2008-11-01)

Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China
by: Birendra Kumar Sah, et al.
Published: (2021-01-01)

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer
by: Akari Hashimoto, et al.
Published: (2014-05-01)

Adenocarcinoma in bladder diverticulum, metastatic from gastric cancer
by: Shimokawa Kuniyasu, et al.
Published: (2005-08-01)

Hearing loss as an unusual consequence of metastatic gastric adenocarcinoma
by: CE Owers, et al.
Published: (2010-10-01)

Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma
by: Li Xiao-qiang, et al.
Published: (2009-04-01)

Programmed chemotherapy for patients with metastatic unresectable gastric cancer.
by: Masataka Shinoda, et al.
Published: (2012-01-01)

The Effect of Compound Sophora on Fluorouracil and Oxaliplatin Resistance in Colorectal Cancer Cells
by: WeiHua Yin, et al.
Published: (2019-01-01)

Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts
by: Deukchae Na, et al.
Published: (2021-08-01)

Neoadjuvant chemotherapy of epirobicin, oxaliplatin, capecitabine regimen in patients with advanced gastric cancer: a two year study
by: Samiei F, et al.
Published: (2012-10-01)

Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
by: Jang Ho Cho, et al.
Published: (2017-01-01)

Oxaliplatin-Induced Lhermitte’s Sign in Gastric Cancer
by: Takeshi Okamoto, et al.
Published: (2020-01-01)

The biological significance and clinical implication of KRAS mutant-mediated oxaliplatin chemotherapy sensitivity in metastatic colorectal cancer (mCRC)
by: Yu-Lin Lin, et al.
Published: (2014)